Eli Lilly’s partnership with InnoCare Pharma follows deals struck this year with other China-based companies. While indications for the new alliance remain undisclosed, InnoCare specializes in oncology and autoimmune drugs.
The post Lilly Again Looks to China for New Drugs, Paying InnoCare $100M to Start R&D Pact appeared first on MedCity News.
